The Vanguard Group's Securities Disclosure on Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc under Form 8.3, as required by the Irish Takeover Panel Act of 1997. This disclosure covers interests in relevant securities amounting to 1% or more. The document, dated January 2, 2026, outlines Vanguard's current holding in Avadel, which consists of 5,861,488 US$0.01 ordinary shares, representing a 6.02% interest.

In recent trading activity, Vanguard purchased 1,560 shares at $21.52 each and sold 4,853 shares at the same price. Vanguard currently holds no cash-settled derivatives or stock-settled derivatives related to Avadel. The form indicates no existing indemnity or dealing arrangements nor any agreements related to options or derivatives concerning Avadel's securities.